(MedPage Today) — ORLANDO — Anti-interleukin (IL)-5 receptor alpha monoclonal antibody benralizumab (Fasenra) reduced flares in hypereosinophilic syndrome (HES), the phase III NATRON trial showed.
Once-monthly injections reduced risk of a…
Source link : https://www.medpagetoday.com/meetingcoverage/acaai/118393
Author :
Publish date : 2025-11-09 13:17:00
Copyright for syndicated content belongs to the linked Source.
